Bactericidal Permeability Protein Inhibitor and Interleukin-1beta Levels After Non-surgical Periodontal Treatment

Periodontitis Clinical Trial

Official title:

Gingival Crevicular Fluid (GCF) Bactericidal/Permeability-increasing Protein (BPI) and Interleukin (IL)-1beta in Periodontitis Patients: Non-surgical Periodontal Treatment Effects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06354504
• Other study ID #: 20.02.2019/177
• Status: Completed
• Phase: N/A
• Start date: November 19, 2019
• Est. completion date: September 20, 2020

Study information

• Verified date: April 2024
• Source: Akdeniz University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study was to examine the relationship between healing response after non-surgical periodontal treatment and baseline gingival crevicular fluid (GCF) levels of bactericidal/permeability-increasing protein (BPI) and interleukin-1beta (IL-1ß).

Description:

Bactericidal/permeability-increasing proteins (BPI) specific and powerful effect against Gram negative bacteria and their LPSs is completely observable in biological fluids such as plasma, serum, and whole blood.

Objective: It is the evaluation of periodontal disease effect of BPI and interleukin-1 beta (IL-1 β) levels in gingival fluid before and after non-surgical periodontal treatment (NSPT)in patients with periodontal disease.

Method: Thirty systemically healthy and non-smoking individuals with periodontitis were included in the study. Before NSPT, the clinical parameters of plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAS), bleeding on probing (BOP) were measured. The gingival fluid samples were taken using the paper strip method. The same procedures were repeated at 6 weeks and 6 months after non-surgical periodontal treatment. ELISA method was used for the analysis of the samples

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 20, 2020
• Est. primary completion date: September 20, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 64 Years

Eligibility

Inclusion Criteria

Systemically healthy,

• Stage II or III, Grade A periodontitis

• Having at least 20 permanent teeth (excluding third molars and any tooth loss induced by -non-periodontal causes).

Exclusion Criteria:

Smoking,

• use of alcohol; pregnancy or lactation; intake ofantibiotics, steroidal or non-steroidal anti-inflammatory drugs within the last 6 months

• having received periodontal treatment within the last 6 months

Related Conditions & MeSH terms

• Periodontitis

Intervention

Procedure:
• Non-surgical periodontal treatment
Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure

Locations

Country	Name	City	State
Turkey	Akdeniz Üniversitesi Dis Hekimligi Fakültesi	Antalya
Turkey	Akdeniz Üniversity	Antalya

Sponsors (1)

Lead Sponsor	Collaborator
Akdeniz University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gingival crevicular fluid Bactericidal/permeability-increasing proteins levels	Gingival Crevicular Fluid Bactericidal Permeability Increasing Protein levels in periodonitis patients after Non-surgical periodontal treatment	through study completion, an average of 1 year
Secondary	Gingival crevicular fluid interleukin-1Beta levels	Gingival Crevicular Fluid IL-1ß in periodonitis patients after Non-surgical periodontal treatment	through study completion, an average of 1 year